Imugene Ltd (IMU) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Imugene Ltd (IMU) has a cash flow conversion efficiency ratio of -0.620x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-25.97 Million ≈ $-18.38 Million USD) by net assets (AU$41.87 Million ≈ $29.62 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Imugene Ltd (IMU) balance sheet quality index to measure how much of total assets are equity-financed.
Imugene Ltd - Cash Flow Conversion Efficiency Trend (1993–2025)
This chart illustrates how Imugene Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of Imugene Ltd to evaluate the quality of earnings relative to operating cash generation.
Imugene Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Imugene Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Talam Transform Bhd
KLSE:2259
|
-0.018x |
|
HAMILTON GLB.OPP.LS-0001
F:5DS
|
N/A |
|
GEE Group Inc
NYSE MKT:JOB
|
-0.024x |
|
Argent Minerals Ltd
AU:ARD
|
-0.260x |
|
OptiCept Technologies AB
ST:OPTI
|
-0.050x |
|
QPM Energy Ltd
AU:QPM
|
-0.108x |
|
Hultström Group B
ST:HULT-B
|
0.112x |
|
Resaas Services Inc
V:RSS
|
-0.022x |
Annual Cash Flow Conversion Efficiency for Imugene Ltd (1993–2025)
The table below shows the annual cash flow conversion efficiency of Imugene Ltd from 1993 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Imugene Ltd.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$45.03 Million ≈ $31.86 Million |
AU$-75.57 Million ≈ $-53.47 Million |
-1.678x | -95.07% |
| 2024-06-30 | AU$118.25 Million ≈ $83.67 Million |
AU$-101.73 Million ≈ $-71.98 Million |
-0.860x | -447.78% |
| 2023-06-30 | AU$189.63 Million ≈ $134.17 Million |
AU$-29.78 Million ≈ $-21.07 Million |
-0.157x | +28.98% |
| 2022-06-30 | AU$138.70 Million ≈ $98.14 Million |
AU$-30.67 Million ≈ $-21.70 Million |
-0.221x | -9.50% |
| 2021-06-30 | AU$65.02 Million ≈ $46.00 Million |
AU$-13.13 Million ≈ $-9.29 Million |
-0.202x | -19.19% |
| 2020-06-30 | AU$59.81 Million ≈ $42.32 Million |
AU$-10.13 Million ≈ $-7.17 Million |
-0.169x | +41.54% |
| 2019-06-30 | AU$27.29 Million ≈ $19.31 Million |
AU$-7.91 Million ≈ $-5.60 Million |
-0.290x | +0.52% |
| 2018-06-30 | AU$15.48 Million ≈ $10.95 Million |
AU$-4.51 Million ≈ $-3.19 Million |
-0.291x | -24.18% |
| 2017-06-30 | AU$11.39 Million ≈ $8.06 Million |
AU$-2.67 Million ≈ $-1.89 Million |
-0.235x | +39.56% |
| 2016-06-30 | AU$7.86 Million ≈ $5.56 Million |
AU$-3.05 Million ≈ $-2.16 Million |
-0.388x | -46.86% |
| 2015-06-30 | AU$7.73 Million ≈ $5.47 Million |
AU$-2.04 Million ≈ $-1.45 Million |
-0.264x | -55.52% |
| 2014-06-30 | AU$6.73 Million ≈ $4.76 Million |
AU$-1.14 Million ≈ $-809.52K |
-0.170x | +76.58% |
| 2013-06-30 | AU$1.89 Million ≈ $1.33 Million |
AU$-1.37 Million ≈ $-968.40K |
-0.726x | +19.38% |
| 2012-06-30 | AU$1.07 Million ≈ $759.51K |
AU$-965.92K ≈ $-683.45K |
-0.900x | -447.17% |
| 2011-06-30 | AU$4.21 Million ≈ $2.98 Million |
AU$1.09 Million ≈ $771.53K |
0.259x | +156.39% |
| 2010-06-30 | AU$3.79 Million ≈ $2.68 Million |
AU$-1.74 Million ≈ $-1.23 Million |
-0.460x | -377.67% |
| 2009-06-30 | AU$5.33 Million ≈ $3.77 Million |
AU$881.77K ≈ $623.91K |
0.166x | +160.74% |
| 2008-06-30 | AU$4.67 Million ≈ $3.30 Million |
AU$-1.27 Million ≈ $-900.66K |
-0.273x | +24.77% |
| 2007-06-30 | AU$4.70 Million ≈ $3.33 Million |
AU$-1.70 Million ≈ $-1.20 Million |
-0.362x | -27.73% |
| 2006-06-30 | AU$6.46 Million ≈ $4.57 Million |
AU$-1.83 Million ≈ $-1.30 Million |
-0.284x | -50.67% |
| 2005-06-30 | AU$8.65 Million ≈ $6.12 Million |
AU$-1.63 Million ≈ $-1.15 Million |
-0.188x | +32.68% |
| 2004-06-30 | AU$5.43 Million ≈ $3.84 Million |
AU$-1.52 Million ≈ $-1.07 Million |
-0.280x | +71.84% |
| 2002-06-30 | AU$792.83K ≈ $560.98K |
AU$-787.36K ≈ $-557.11K |
-0.993x | -108.81% |
| 2001-06-30 | AU$-226.54K ≈ $-160.29K |
AU$-2.55 Million ≈ $-1.81 Million |
11.266x | +892.20% |
| 2000-06-30 | AU$2.78 Million ≈ $1.97 Million |
AU$-3.95 Million ≈ $-2.80 Million |
-1.422x | -147.09% |
| 1999-06-30 | AU$6.00 Million ≈ $4.24 Million |
AU$-3.45 Million ≈ $-2.44 Million |
-0.576x | -99.40% |
| 1997-06-30 | AU$7.45 Million ≈ $5.27 Million |
AU$-2.15 Million ≈ $-1.52 Million |
-0.289x | -16.06% |
| 1996-06-30 | AU$8.12 Million ≈ $5.75 Million |
AU$-2.02 Million ≈ $-1.43 Million |
-0.249x | -58.27% |
| 1995-06-30 | AU$10.62 Million ≈ $7.52 Million |
AU$-1.67 Million ≈ $-1.18 Million |
-0.157x | -20.81% |
| 1994-06-30 | AU$11.19 Million ≈ $7.91 Million |
AU$-1.46 Million ≈ $-1.03 Million |
-0.130x | -235.76% |
| 1993-06-30 | AU$5.11 Million ≈ $3.62 Million |
AU$-198.00K ≈ $-140.10K |
-0.039x | -- |
About Imugene Ltd
Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA,… Read more